In particular, IGF1R activation/overexpression, which appears in approximately 50% of all breast cancer cases and up to 65% of ErbB2+ breast cancers, is correlated with decreased survival in patients with ErbB2+ breast cancer—presumably because of the presence and activation of the IGF1R pathway for alternative downstream signaling [47–49]. Here, ERBB2 is linked to breast carcinoma.